Gary Lichtenstein

There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring…

There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring…

BACKGROUND: Gut dysbiosis is associated with persistent multi-system symptoms following SARS-CoV-2 infection, or post-acute COVID-19 syndrome (PACS). We performed a randomised controlled trial to assess the effects of gut microbiome modulation on alleviation of PACS symptoms…

The Phase 3 QUASAR Maintenance Study (NCT04033445) is a randomized-withdrawal, double-blind, placebo(PBO)-controlled, study that evaluated the efficacy and safety of maintenance treatment with subcutaneous (SC) guselkumab (GUS), an IL-23p19 subunit antagonist, in patients (pts) with moderately to s…

SOCIETY: AGA

There are several complex clinical scenarios in the management of IBD. This session will address some of the most pressing clinical challenges in this population including the management of dysplasia, mild disease, and extraintestinal manifestations…